Event is Happening Now!
The Great National Cancer Vaccine Summit
09:00 am
01 May, 2024
15 Hatfields Conference Centre, London SE1 8DJ
The Great National Cancer Vaccine Summit
09:00 am
01 May, 2024
15 Hatfields Conference Centre, London SE1 8DJ
300
Delegates Registered
Job titles includes
Deputy Head of Cancer Clinical Trials Unit
Director Policy & Communications Oncology
Head of Cancer Alliance
Head of Cancer Norfolk and Waveney ICB
Head of Clinical Research Delivery
Head of Clinical Research Performance and Quality
Consultant
Consultant clinical oncologist
Consultant Histopathologist
Consultant Medical Oncologist
Consultant ophthalmologist
CSO & Co-Founder
Organisations Involved
Chelsea and Westminster Hospital NHS Trust
Guy's and St Thomas' Hospital
Kings college hospital
Barking Havering Redbridge NHS Trust
University College London Hospital
Warrington and Halton NHS Trust
Weston Park Hospital Sheffield
Harrogate and District NHS Foundation Trust
Torbay and South Devon NHS trust
Hull Royal Infirmary
Moorfields Eye Hospital
Royal Surrey Hospital
The UK is pioneering a unique National Cancer Vaccine Advance. This groundbreaking strategy could transform the outcomes of patients with cancer. It involves placing 10,000 patients through clinical trials by 2030. Doctors will utilise mRNA technology used to make coronavirus vaccines and use the technology to trial in cancer patients. If achieved, it will bring the UK back into the global vaccine main stage. These advances made by our country are potentially of historical level achievement, and the most tangible silver lining of our experiences in recent years.
The Great National Cancer Vaccine Summit will showcase the incredible progress and achievements around the country. We know that the most brilliant people have been working very hard in our best cancer centres, within the most agile organisations to give this advance a chance of success. The conference aims to foster a collaborative environment that encourages the exchange of knowledge, best practices, and innovative approaches to help people affected by cancer.
With attendees from industry, government, public sector, academia, research system and of course healthcare, together we will delve into the intricacies of this incredible national cancer vaccine advance that has captured the public imagination. The Great National Cancer Vaccine Summit seeks to underscore the global implications, paving the way for international collaborations and partnerships aimed at redefining the future of cancer care on a global scale.
Key Challenges:
- Personalisation of cancer vaccines for individual patients
- Ensuring access and speed of new clinical trials
- Integrating new treatment methodologies seamlessly into existing cancer care pathways
Potential Outcomes:
- Enhanced quality of life for cancer patients
- A new model of cancer care that is safer and provides better use of cancer treatment centres.
- Facilitation of quicker, more comfortable, and personalised care for patients
As we celebrate the first year of this significant leap into the future with cancer vaccines, the NHS extends a heartfelt invitation to all oncology specialists and senior leaders to join us at this pivotal conference.
Embrace the opportunity to be at the forefront of groundbreaking advancements in immunotherapy and contribute to shaping the future of cancer care on a global scale.
Registration is free for all NHS oncology specialists, NHS staff, and public sector senior leaders and teams, so secure your place today and be a part of this momentous event that is set to shape the future of cancer treatment.
Headline Sponsor
The Great National Cancer Vaccine Summit Key Subjects
- How the UK is aspiring to be a Life Sciences and a mRNA vaccine superpower?
- Why the government deployed its vaccine taskforce model on cancer vaccines?
- What have we achieved one year into this national cancer vaccine advance?
- The patient perspective- do we really want cancer vaccines, and will we wait?
- Advancements in RNA-based immunotherapies/vaccines and their integration into cancer treatment strategies- the genomics laboratories of the future.
- Our UK cancer vaccine start-ups with ambitions to transform cancer care.
- Lessons learnt from leading cancer vaccine forums in ensuring fast trial delivery.
- Benefits and challenges associated with cancer vaccines. Lessons learnt from our very best cancer centres.
- The clinical debate- has industry got it right in terms of cancer vaccine trial design and/or cancer trial subtypes.
- What has our regional centres of excellence in cancer vaccines achieved?
- The nursing research staff- what was needed and what was it like to give a cancer vaccine?
- From treating cancer, to preventing infections- how might prophylaxis eradicate infections in cancer patients?
- The trial leads update- flash metrics and the unstoppable tempo of achievements.
- The scientific basis of mRNA vaccines in cancer treatment, their mode of action, and the look ahead into the next ten years.
- How industry is working with healthcare systems to ensure that UK patients can get rapid access to novel trials and drugs.
- The scientific story- ways the cancer vaccine of tomorrow will be better.
- The final assessment- are we on course to hit the government ambitions for our national cancer vaccine advance- 10,000 patients by 2030, initiating a global advance, and launching trials across early/late stage cancers and across multiple subtypes
Who will Attend
- Medical oncologists
- Clinical oncologist
- Cancer surgeons
- Cancer trialists
- Cancer vaccine researchers
- Cancer trials Unit
- Cancer alliances
- NHS Hospital leaderships
- Public sector research leadership
- Government Officials
Your Pass Includes....
- Multiple live keynote presentations
- Live examples of both NHS and Commercial best practice
- Breakfast, Lunch and Refreshments included
- Meet the supplier sessions.
- Networking opportunity
- Live Q&A sessions with all speakers on the day
- Drinks receptions (subject to event)
- CPD accreditation
- Prize draws
Speakers
Dr Jonathan Buckley
Cancer Research Team Leader
Professor Christian Ottensmeier
Professor of Immuno-Oncology, Molecular & Clinical Cancer Medicine / Consultant Medical Oncologist
Thomas Powles
Professor/Director of Barts Cancer Centre
Sponsors & Partners
The Agenda
09:00
Registration and Breakfast
Registration - Open from 9:00 am - Closes at 11:00 am
All delegates must complete their registration process before the 11:00 AM cut-off time. Please arrive in a timely manner to allow for registration and to avoid any inconvenience. Delegates who arrive after the registration deadline will be refused entry to the event.
We appreciate your cooperation in helping us maintain the event's schedule and ensuring that everyone can fully participate in the Great National Cancer Vaccine Conference. If you have any questions or require assistance, our event staff will be available to assist you with the registration process.
Thank you for your understanding, and we look forward to an insightful and productive event together!
10:00
Chair Opening Address (Confirmed)
Dr Lennard YW Lee
Associate Professor (University of Oxford), Medical Oncologist (NHS), National Clinical Advisor (Office for Life Sciences)
University of Oxford
Chair Opening Address (Confirmed)
10:05
Keynote Presentation - Lessons from the Covid Vaccine Taskforce in 2020 (Confirmed)
Kate Bingham
Managing Partner
SV Health Investors
Synopsis TBC
10:20
Keynote Presentation - Working in partnership- how successful UK PIs excel in cancer research, and relevance to cancer vaccines (Confirmed)
Thomas Powles
Professor/Director of Barts Cancer Centre
QMUL
Keynote Presentation - Working in partnership- how successful UK PIs excel in cancer research, and relevance to cancer vaccines (Confirmed)
10:35
Keynote Presentation - Personalized vaccination with viral vectors: NOUS-PEV (Confirmed)
Dr Stefan N Symeonides
Consultant Medical Oncologist / Senior Lecturer in Experimental Cancer Medicine
University of Edinburgh
I will present the in-press findings from the NOUS-PEV Phase I trial, with a focus on the translational results, including the neoantigen specific T cell response in the tumour
10:50
Keynote Presentation - Dr. Heather Shaw, Consultant Medical Oncologist, UCL (Confirmed)
Dr Heather Shaw
Consultant Medical Oncologist
University College London Hospital and Mount Vernon Cancer Centre
Keynote Presentation - Dr. Heather Shaw, Consultant Medical Oncologist, UCL (Confirmed)
11:05
Keynote Presentation - Why and when should we use cancer vaccines? Lung Cancer as an exemplar (Confirmed)
Gary Middleton
Professor of Medical Oncology
University of Birmingham
Lung Cancer is one of the top 10 causes of death globally. 14% of global death is caused by infections, and contributes 3 of these top 10 causes. and for many of these there are effective vaccines. Whilst much earlier vaccine development in lung cancer focussed on the advanced disease setting it is clear that much more traction in this space will be in their use in the setting of minimal residual disease or perhaps most profitably, as in the area of communicable diseases, in aiming at prevention. A key exemplar UK project will be discussed.
11:20
Morning Break
Morning Break
12:20
Chair Morning Reflection (Confirmed)
Dr Lennard YW Lee
Associate Professor (University of Oxford), Medical Oncologist (NHS), National Clinical Advisor (Office for Life Sciences)
University of Oxford
Chair Morning Reflection (Confirmed)
12:25
Case Study
Case Study
12:45
Case Study
Case Study
13:05
Keynote Presentation - Professor Christian Ottensmeier (Confirmed)
Professor Christian Ottensmeier
Professor of Immuno-Oncology, Molecular & Clinical Cancer Medicine / Consultant Medical Oncologist
University of Liverpool / Clatterbridge Cancer Centre
With decades of experience investigating immune responses, Professor Ottesnmeier will share an overview of the successes and challenges leading us to where we are now in cancer vaccine immunology. As a chief investigator on UK vaccine trials and top recruiter in multiple settings, he will share clinical experiences of cancer vaccine trials and explore the path onwards in the national vaccine advance.
13:20
Case Study
Case Study
13:40
Networking & Lunch
Networking & Lunch
14:40
Chair Afternoon Address (Confirmed)
Dr Lennard YW Lee
Associate Professor (University of Oxford), Medical Oncologist (NHS), National Clinical Advisor (Office for Life Sciences)
University of Oxford
Chair Afternoon Address (Confirmed)
14:45
Overcoming obstacles for cancer vaccine trial execution (Confirmed)
Rob Jones
Consultant Liver Surgeon & Associate Professor of Surgery
University of Liverpool
Mr Rob Jones, a chief investigator for a BioNTech cancer vaccine trial, will speak around navigating the roll out of cancer vaccine trials in the UK. Cancer vaccine trials bring a unique set of challenges, and this sessions aims to highlight obstacles and solutions for implementation and recruitment.
15:05
Keynote Presentation - The National Cancer Vaccines Research Programme (Confirmed)
Professor Sarah Danson
Professor of Medical Oncology
University of Sheffield
The UK has formed two strategic partnerships, with BioNTech and Moderna, to deliver cancer vaccine research. A Vaccine Innovation Pathway has been created with a vision to make the UK the best place globally to do vaccine research. Sarah Danson, Sheffield and Pippa Corrie, Cambridge act as co-clinical leads for the cancer component.
We have formed a Cancer Vaccine Research Forum and a National Cancer Vaccine Delivery Group. We work closely with Pharma and Principal Investigators to set up and deliver cancer vaccine trials using the extensive UK research infrastructure. This talk will cover the network approach used so far and future plans to support cancer vaccine trials.
15:20
Keynote Presentation -Â Can we deliver big vaccine trials in smaller centres? (Confirmed)
Dr Jonathan Buckley
Cancer Research Team Leader
Torbay and South Devon NHS Foundation Trust
Dr Nangi Lo
Consultant Medical Oncologist
Torbay and South Devon NHS Foundation Trust
The session concludes with a discussion on the transformative impact of widespread participation in cancer vaccine trials, not only for the individuals involved but also for the region's standing in the global map of cancer research and innovation.
15:35
Science Panel - Future gazing the technology developments
Science Panel - Future gazing the technology developments
- Professor Tim Elliott FMedSci , Kidani Professor of Immuno-oncology and Fellow of Oriel College , Director, Centre for Immuno-oncology , Co-Director of Oxford Cancer and the CRUK Oxford Centre (Provisionally Confirmed)
16:05
Networking
Networking
17:25
End of Day
End of Day
Book your Place
Paid Tickets
Ticket
Price
Quantity
Private Sector (In-Person)
£406.99 excl VAT
Unlimited Places
Unlimited Places
0
